NCT05020236
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05020236
Title A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (MAGNETISMM-5)
Acronym MAGNETISMM-5
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Pfizer
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG


No variant requirements are available.